118 related articles for article (PubMed ID: 37609256)
61. YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.
Tsuchiya K; Yoshimura K; Inoue Y; Iwashita Y; Yamada H; Kawase A; Watanabe T; Tanahashi M; Ogawa H; Funai K; Shinmura K; Suda T; Sugimura H
Oncoimmunology; 2021; 10(1):1962656. PubMed ID: 34408926
[TBL] [Abstract][Full Text] [Related]
62. c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4.
González-Prieto R; Cuijpers SA; Kumar R; Hendriks IA; Vertegaal AC
Cell Cycle; 2015; 14(12):1859-72. PubMed ID: 25895136
[TBL] [Abstract][Full Text] [Related]
63. PIAS1 and TIF1γ collaborate to promote SnoN SUMOylation and suppression of epithelial-mesenchymal transition.
Chanda A; Ikeuchi Y; Karve K; Sarkar A; Chandhoke AS; Deng L; Bonni A; Bonni S
Cell Death Differ; 2021 Jan; 28(1):267-282. PubMed ID: 32770107
[TBL] [Abstract][Full Text] [Related]
64. PIAS1 interacts with and represses SOX9 transactivation activity.
Oh HJ; Kido T; Lau YF
Mol Reprod Dev; 2007 Nov; 74(11):1446-55. PubMed ID: 17440973
[TBL] [Abstract][Full Text] [Related]
65. The ND10 Component Promyelocytic Leukemia Protein Acts as an E3 Ligase for SUMOylation of the Major Immediate Early Protein IE1 of Human Cytomegalovirus.
Reuter N; Schilling EM; Scherer M; Müller R; Stamminger T
J Virol; 2017 May; 91(10):. PubMed ID: 28250117
[TBL] [Abstract][Full Text] [Related]
66. Suppression of m
Li Z; Qian P; Shao W; Shi H; He XC; Gogol M; Yu Z; Wang Y; Qi M; Zhu Y; Perry JM; Zhang K; Tao F; Zhou K; Hu D; Han Y; Zhao C; Alexander R; Xu H; Chen S; Peak A; Hall K; Peterson M; Perera A; Haug JS; Parmely T; Li H; Shen B; Zeitlinger J; He C; Li L
Cell Res; 2018 Sep; 28(9):904-917. PubMed ID: 30065315
[TBL] [Abstract][Full Text] [Related]
67. The SUMO E3-ligase PIAS1 couples reactive oxygen species-dependent JNK activation to oxidative cell death.
Leitao BB; Jones MC; Brosens JJ
FASEB J; 2011 Oct; 25(10):3416-25. PubMed ID: 21676946
[TBL] [Abstract][Full Text] [Related]
68. The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity.
Ma S; Yan J; Barr T; Zhang J; Chen Z; Wang LS; Sun JC; Chen J; Caligiuri MA; Yu J
J Exp Med; 2021 Aug; 218(8):. PubMed ID: 34160549
[TBL] [Abstract][Full Text] [Related]
69. The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells.
Dixit D; Prager BC; Gimple RC; Poh HX; Wang Y; Wu Q; Qiu Z; Kidwell RL; Kim LJY; Xie Q; Vitting-Seerup K; Bhargava S; Dong Z; Jiang L; Zhu Z; Hamerlik P; Jaffrey SR; Zhao JC; Wang X; Rich JN
Cancer Discov; 2021 Feb; 11(2):480-499. PubMed ID: 33023892
[TBL] [Abstract][Full Text] [Related]
70. Decreased
Luo Q; Gao Y; Zhang L; Rao J; Guo Y; Huang Z; Li J
Biomed Res Int; 2020; 2020():5735279. PubMed ID: 32884942
[TBL] [Abstract][Full Text] [Related]
71. Cellular RNA Helicase DHX9 Interacts with the Essential Epstein-Barr Virus (EBV) Protein SM and Restricts EBV Lytic Replication.
Fu W; Verma D; Burton A; Swaminathan S
J Virol; 2019 Feb; 93(4):. PubMed ID: 30541834
[TBL] [Abstract][Full Text] [Related]
72. N
Dong G; Liang Y; Chen B; Zhang T; Wang H; Chen Y; Zhang Y; Jiang F; Wang Y
Thorac Cancer; 2023 Oct; 14(29):2962-2975. PubMed ID: 37669906
[TBL] [Abstract][Full Text] [Related]
73. YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis.
Hua Z; Wei R; Guo M; Lin Z; Yu X; Li X; Gu C; Yang Y
Oncogene; 2022 Mar; 41(10):1482-1491. PubMed ID: 35075244
[TBL] [Abstract][Full Text] [Related]
74. METTL3-regulated m6A modification impairs the decidualization of endometrial stromal cells by regulating YTHDF2-mediated degradation of FOXO1 mRNA in endometriosis-related infertility.
Li X; Jin J; Long X; Weng R; Xiong W; Liang J; Liu J; Sun J; Cai X; Zhang L; Liu Y
Reprod Biol Endocrinol; 2023 Oct; 21(1):99. PubMed ID: 37891533
[TBL] [Abstract][Full Text] [Related]
75. Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities.
Ibata M; Iwasaki J; Fujioka Y; Nakagawa K; Darmanin S; Onozawa M; Hashimoto D; Ohba Y; Hatakeyama S; Teshima T; Kondo T
Cancer Sci; 2017 Feb; 108(2):200-207. PubMed ID: 27960034
[TBL] [Abstract][Full Text] [Related]
76. Heterogeneous Nuclear Protein U Degraded the m
Zhou H; Yan Y; Gao J; Ma M; Liu Y; Shi X; Zhang Q; Xu X
J Virol; 2023 Feb; 97(2):e0175122. PubMed ID: 36752613
[TBL] [Abstract][Full Text] [Related]
77. Enhancing recombinant protein and viral vector production in mammalian cells by targeting the YTHDF readers of N
Lao N; Barron N
Biotechnol J; 2023 Apr; 18(4):e2200451. PubMed ID: 36692010
[TBL] [Abstract][Full Text] [Related]
78. Site-specific SUMOylation of viral polymerase processivity factor: a way of localizingtoND10 subnuclear domains for restricted and self-controlled reproduction of herpesvirus.
Lai S; Xu M; Wang Y; Li R; Xia C; Xia S; Chen J
Virulence; 2021 Dec; 12(1):2883-2901. PubMed ID: 34747321
[TBL] [Abstract][Full Text] [Related]
79. The RNA helicase DDX5 promotes viral infection via regulating N6-methyladenosine levels on the DHX58 and NFκB transcripts to dampen antiviral innate immunity.
Xu J; Cai Y; Ma Z; Jiang B; Liu W; Cheng J; Guo N; Wang Z; Sealy JE; Song C; Wang X; Li Y
PLoS Pathog; 2021 Apr; 17(4):e1009530. PubMed ID: 33909701
[TBL] [Abstract][Full Text] [Related]
80. RNA m
Zheng X; Wang J; Zhang X; Fu Y; Peng Q; Lu J; Wei L; Li Z; Liu C; Wu Y; Yan Q; Ma J
Immun Inflamm Dis; 2021 Jun; 9(2):351-362. PubMed ID: 33434416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
